Scullion Kathleen M, Vliegenthart A D Bastiaan, Rivoli Laura, Oosthuyzen Wilna, Farrah Tariq E, Czopek Alicja, Webb David J, Hunter Robert W, Bailey Matthew A, Dhaun Neeraj, Dear James W
University/British Heart Foundation Centre of Research Excellence, Centre for Cardiovascular Science, University of Edinburgh, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, UK.
iScience. 2020 Dec 13;24(1):101937. doi: 10.1016/j.isci.2020.101937. eCollection 2021 Jan 22.
Vascular and kidney dysfunction commonly co-exist. There is a need for biomarkers of vascular health. Circulating microRNAs are biomarkers; miR-126 is endothelial cell-enriched. We measured circulating miR-126 in rats with nephrotoxic nephritis (NTN) and humans with acute endothelial and renal injury (vasculitis associated with autoantibodies to neutrophil cytoplasm antigens (ANCAs)). We compared these findings to those from patients with chronic kidney disease (CKD) and end-stage renal disease (ESRD) and explored the relationship between miR-126 and vascular dysfunction. In NTN, miR-126 was reduced. In ANCA vasculitis (N = 70), pre-treatment miR-126 was reduced compared to health (N = 60) (88-fold). miR-126 increased 3.4-fold post-treatment but remained lower than in health (∼26-fold). Argonaute 2-bound miR-126 increased with ANCA vasculitis treatment. miR-126 did not differ between CKD (N = 30) and health but its concentration correlated with endothelial dysfunction. miR-126 was reduced in ESRD (N = 15) (∼350 fold). miR-126 may be a marker of vascular inflammation and could aid decision-making.
血管功能障碍和肾脏功能障碍通常同时存在。需要血管健康的生物标志物。循环微RNA就是生物标志物；miR-126在内皮细胞中含量丰富。我们检测了肾毒性肾炎（NTN）大鼠以及患有急性内皮和肾脏损伤（与抗中性粒细胞胞浆抗原（ANCA）自身抗体相关的血管炎）的人类体内的循环miR-126。我们将这些结果与慢性肾脏病（CKD）和终末期肾病（ESRD）患者的结果进行比较，并探讨miR-126与血管功能障碍之间的关系。在NTN中，miR-126降低。在ANCA血管炎患者（N = 70）中，治疗前的miR-126与健康人群（N = 60）相比降低了（88倍）。治疗后miR-126升高了3.4倍，但仍低于健康人群（约26倍）。与ANCA血管炎治疗相关的AGO2结合的miR-126增加。CKD患者（N = 30）与健康人群的miR-126没有差异，但其浓度与内皮功能障碍相关。ESRD患者（N = 15）的miR-126降低（约350倍）。miR-126可能是血管炎症的标志物，有助于决策。
